Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.

Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J

Diabetes care23 Mar 2010Cited by 129 (Europe PMC)

PMID20332351PMCIDPMC2875443DOI10.2337/dc09-2260PepBankPUB-20332351

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on oral agents, switching from twice-daily exenatide to once-daily liraglutide further reduced A1C by 0.32%.
In plain wordsIn adults with type 2 diabetes, switching from exenatide to liraglutide lowered A1C further.
Peptide
Liraglutide
Outcome
DecreaseA1C change after switch from exenatide
Study
n: not reported in source
Comparator
Before switch (exenatide)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 14 weeksAs given in this study (human).
Measurements
A1C change
0.32%
switch to liraglutide
Source sentences
Summary
Switching from exenatide to liraglutide further and significantly reduced A1C (0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmHg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Report a problemFND-2033235101
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on oral agents, switching from exenatide to liraglutide further reduced fasting plasma glucose by 0.9 mmol/l.
In plain wordsIn adults with type 2 diabetes, switching from exenatide to liraglutide lowered fasting blood glucose further.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change after switch
Study
n: not reported in source
Comparator
Before switch (exenatide)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 14 weeksAs given in this study (human).
Measurements
FPG change
0.9 mmol/l
switch to liraglutide
Source sentences
Summary
Switching from exenatide to liraglutide further and significantly reduced A1C (0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmHg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Report a problemFND-2033235102
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on oral agents, switching from exenatide to liraglutide further reduced body weight by 0.9 kg.
In plain wordsIn adults with type 2 diabetes, switching from exenatide to liraglutide led to a further small weight loss.
Peptide
Liraglutide
Outcome
DecreaseBody weight change after switch
Study
n: not reported in source
Comparator
Before switch (exenatide)
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 14 weeksAs given in this study (human).
Measurements
Weight change
0.9 kg
switch to liraglutide
Source sentences
Summary
Switching from exenatide to liraglutide further and significantly reduced A1C (0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmHg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Report a problemFND-2033235103
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on oral agents, switching from exenatide to liraglutide further reduced systolic blood pressure by 3.8 mmHg.
In plain wordsIn adults with type 2 diabetes, switching from exenatide to liraglutide lowered systolic blood pressure further.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure change after switch
Study
n: not reported in source
Comparator
Before switch (exenatide)
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.8 mg once daily · subcutaneous · 14 weeksAs given in this study (human).
Measurements
SBP change
3.8 mmHg
switch to liraglutide
Source sentences
Summary
Switching from exenatide to liraglutide further and significantly reduced A1C (0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmHg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Report a problemFND-2033235104
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, minor hypoglycaemia was minimal after switching from exenatide to liraglutide, at 1.30 episodes per patient-year.
In plain wordsAfter switching from exenatide to liraglutide, minor low blood sugar was rare in adults with type 2 diabetes.
Peptide
Liraglutide
Outcome
Not applicableMinor hypoglycaemia after switch
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 14 weeksAs given in this study (human).
Measurements
Minor hypoglycaemia rate
1.3 episodes/patient-year
switch to liraglutide
Source sentences
Summary
Switching from exenatide to liraglutide further and significantly reduced A1C (0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmHg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Report a problemFND-2033235105
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, 3.2% had nausea after switching from exenatide to liraglutide.
In plain wordsAfter switching from exenatide to liraglutide, 3.2% of adults with type 2 diabetes had nausea.
Peptide
Liraglutide
Outcome
Not applicableNausea after switch
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.8 mg once daily · subcutaneous · 14 weeksAs given in this study (human).
Measurements
Nausea
3.2%
switch to liraglutide
Source sentences
Summary
Switching from exenatide to liraglutide further and significantly reduced A1C (0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmHg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Report a problemFND-2033235106
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes who continued liraglutide, body weight fell further by 0.4 kg.
In plain wordsIn adults with type 2 diabetes who stayed on liraglutide, weight fell a little further.
Peptide
Liraglutide
Outcome
DecreaseBody weight change with continued liraglutide
Study
n: not reported in source
Comparator
Before extension (liraglutide)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 14 weeksAs given in this study (human).
Measurements
Weight change
0.4 kg
continued liraglutide
Source sentences
Summary
Among patients continuing liraglutide, further significant decreases in body weight (0.4 kg) and systolic blood pressure (2.2 mmHg) occurred with 0.74 episodes/patient-year of minor hypoglycemia and 1.5% experiencing nausea.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Report a problemFND-2033235107
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes who continued liraglutide, systolic blood pressure fell further by 2.2 mmHg.
In plain wordsIn adults with type 2 diabetes who stayed on liraglutide, systolic blood pressure fell a little further.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure change with continued liraglutide
Study
n: not reported in source
Comparator
Before extension (liraglutide)
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 14 weeksAs given in this study (human).
Measurements
SBP change
2.2 mmHg
continued liraglutide
Source sentences
Summary
Among patients continuing liraglutide, further significant decreases in body weight (0.4 kg) and systolic blood pressure (2.2 mmHg) occurred with 0.74 episodes/patient-year of minor hypoglycemia and 1.5% experiencing nausea.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Report a problemFND-2033235108
09HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes who continued liraglutide, minor hypoglycaemia occurred at 0.74 episodes per patient-year.
In plain wordsAdults with type 2 diabetes who stayed on liraglutide had few minor low blood sugar episodes.
Peptide
Liraglutide
Outcome
Not applicableMinor hypoglycaemia with continued liraglutide
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 14 weeksAs given in this study (human).
Measurements
Minor hypoglycaemia rate
0.74 episodes/patient-year
continued liraglutide
Source sentences
Summary
Among patients continuing liraglutide, further significant decreases in body weight (0.4 kg) and systolic blood pressure (2.2 mmHg) occurred with 0.74 episodes/patient-year of minor hypoglycemia and 1.5% experiencing nausea.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Report a problemFND-2033235109
10HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes who continued liraglutide, 1.5% had nausea.
In plain wordsAmong adults with type 2 diabetes who stayed on liraglutide, 1.5% had nausea.
Peptide
Liraglutide
Outcome
Not applicableNausea with continued liraglutide
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 14 weeksAs given in this study (human).
Measurements
Nausea
1.5%
continued liraglutide
Source sentences
Summary
Among patients continuing liraglutide, further significant decreases in body weight (0.4 kg) and systolic blood pressure (2.2 mmHg) occurred with 0.74 episodes/patient-year of minor hypoglycemia and 1.5% experiencing nausea.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide.
Report a problemFND-2033235110

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00518882

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 467Aug 2007 to Apr 2009

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 8 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC